On September 26, 2024, Biogen Inc. announced the termination of its rights under the collaboration and license agreement with Sage Therapeutics, specifically pertaining to the SAGE-324 program. This decision follows the recent announcement of negative results from the Phase 2 KINETIC 2 Study of investigational SAGE-324, which was being developed for the chronic treatment of essential tremor (ET).
As a direct consequence of the unfavorable trial outcomes, further clinical development of SAGE-324 in essential tremor has been discontinued. Essential tremor is a neurological disorder characterized by involuntary, rhythmic shaking, and the failure of SAGE-324 represents a setback in addressing this unmet medical need.
The termination of this collaboration and the cessation of development for SAGE-324 will impact Biogen's pipeline in neurological disorders. This move reflects the inherent risks in drug development and the company's strategy to reallocate resources from programs that do not meet efficacy targets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.